Sanofi Consumer Healthcare India Limited Stock Analysis

Revenue from operations increased 21.6% YoY to Rs. 8,968 million in FY2025, showing strong top-line momentum. / Profit after tax rose 32.7% to Rs. 2,401 million from Rs. 1,810 million, outpacing revenue growth and indicating better operating leverage. / Net profit margin was a strong 26.8%, which supports the view that profitability improved meaningfully during FY2025. / Basic and diluted EPS increased to Rs. 104.27 from Rs. 78.59 in FY2024, reflecting solid per-share earnings growth. / Q4 FY2025 was the strongest quarter with revenue of Rs. 2,556 million and PAT of Rs. 665 million, indicating positive exit momentum into the next period. / The board recommended a final dividend of Rs. 75 per share, equal to a 71.9% payout ratio, signaling confidence in earnings durability.

Exceptional items of negative Rs. 66 million in FY2025 show reported earnings were affected by one-time adjustments, which investors should separate from core profitability. / Operating cash flow, free cash flow, capex, and cash conversion metrics were not disclosed in the extract, limiting assessment of whether Rs. 2,401 million PAT translated into cash. / Debt levels, liquidity ratios, and borrowings data are absent, so financial health cannot be fully validated despite strong profit growth. / No segment-wise revenue distribution or geographic revenue mix was provided, making it difficult to identify concentration risk or the exact sources of the 21.6% growth. / The report extract does not explicitly disclose operational, market, commodity, or competitive risks, which reduces visibility on downside factors for the next 6-12 months. / The company operates as a standalone entity with no subsidiaries, associates, or joint ventures, which simplifies governance but may limit diversification avenues.

Revenue from operations grew 21.6% YoY to Rs. 8,968 million in FY2025 from Rs. 7,375 million in FY2024, indicating strong top-line momentum. / Profit after tax increased 32.7% to Rs. 2,401 million from Rs. 1,810 million, outpacing revenue growth and pointing to better earnings leverage. / Net profit margin stood at 26.8%, a high profitability level for the reported period and evidence of strong bottom-line efficiency. / Basic and diluted EPS both improved to Rs. 104.27 from Rs. 78.59 in FY2024, showing meaningful per-share earnings growth. / Q4 FY2025 was the strongest quarter, with revenue of Rs. 2,556 million and PAT of Rs. 665 million, reinforcing positive near-term momentum. / The company remains a standalone entity with no subsidiaries, associates, or joint ventures, which simplifies the corporate structure and financial reporting.

A negative exceptional item of Rs. 66 million in FY2025 shows reported earnings were affected by one-time adjustments, which slightly clouds comparability. / Dividend per share of Rs. 75 implies a high payout ratio of 71.9%, which supports shareholder returns but could limit retained capital for future expansion. / No cash flow metrics were provided, with operating cash flow, free cash flow, capex, and change in cash all unavailable, making cash generation quality difficult to verify. / Debt, liquidity, and coverage indicators such as debt-to-equity, current ratio, quick ratio, and interest coverage were not disclosed, limiting visibility on financial resilience. / No segment-wise revenue distribution, geographic mix, customer concentration, or supplier concentration data was provided, restricting assessment of concentration and diversification risk. / The report extract did not explicitly discuss operational, market, regulatory, or commodity-related risks, which creates an information gap for risk evaluation.

Revenue from operations increased 21.25% YoY to 8,784 million, showing strong recovery led by successful relaunches of Depura Adult, Combiflam Suspension, Allegra Suspension, and Depura Kids. / Profitability is strong with EBITDA of 3,254 million, EBITDA margin of 36.28%, operating margin of 35.71%, and net profit margin of 26.62%, indicating efficient conversion of sales into earnings. / Balance sheet quality is excellent with debt to equity of 0, debt to assets of 0, cash and cash equivalents of 3,748 million, and total equity of 3,840 million. / Liquidity is robust, with a current ratio of 3.85, quick ratio of 3.37, and working capital of 3,659 million, reducing near-term financial stress. / Free cash flow remained healthy at 1,672 million despite low capex of just 76 million, implying the business is highly cash generative and asset light. / Return metrics are very strong, with ROE at 62.16% and ROA at 43.64%, pointing to strong capital efficiency.

Operating cash flow declined materially to 1,748 million in FY2025 from 4,390 million in FY2024, suggesting weaker cash conversion despite higher accounting profits. / Reported earnings included a non-recurring benefit, as profit after tax of 2,387 million was supported by a 66 million reversal of demerger provisions, with adjusted PAT lower at 2,321 million. / Growth benefited from a low base caused by prior-year product recalls, and export sales growth of 158% for FY2025 and 932% in Q4 may not be fully repeatable once normalization sets in. / The auditor highlighted an emphasis of matter on 111 million of export transactions conducted before shareholder approval for the enhanced related-party transaction limit, indicating governance and compliance sensitivity. / Related-party export exposure increased meaningfully, with the limit for transactions with Opella Healthcare International SAS raised from 1,100 million to 2,000 million, which can elevate counterparty and concentration risk. / The New Labour Codes created an immediate incremental cost of 24 million, and management stated that further impact remains uncertain until Central and State Rules are finalized.

Revenue growth of 21.25% YoY to ₹8,784 million driven by successful relaunch of four recalled products (Depura Adult, Combiflam Suspension, Allegra Suspension, Depura Kids) throughout 2025, with Q4 domestic sales acceleration of 23% demonstrating sustained momentum / Exceptional profitability with net profit margin of 26.62% (PAT of ₹2,387 million) and EBITDA margin of 36.28% (₹3,254 million), reflecting strong pricing power and operational efficiency in consumer healthcare segment / Fortress balance sheet with zero debt (debt-to-equity 0%, debt-to-assets 0%), ₹3,748 million in cash equivalents, and working capital of ₹3,659 million enabling aggressive capital returns (₹1,267 million dividends paid) while maintaining strategic flexibility / Superior return metrics with ROE of 62.16% and ROA of 43.64%, demonstrating exceptional capital efficiency and asset productivity relative to invested capital of ₹3,840 million / Strong cash conversion with free cash flow of ₹1,672 million (18.64% FCF margin, 70.05% conversion ratio) and minimal capex requirements (₹76 million), indicating capital-light business model with high cash generation capability / Export operations showing dramatic 158% YoY growth with transaction limits increased to ₹2,000 million from ₹1,100 million (with shareholder approval), positioning company for sustained international revenue diversification

Earnings quality concerns as 31.8% PAT growth includes ₹66 million exceptional gain from demerger provision reversal, and 158% export growth is partially from a depressed prior-year base when products were recalled, raising sustainability questions / Regulatory compliance red flag: Material related party transactions of ₹111 million with Opella Healthcare International SAS occurred between October 10-28, 2025 but shareholder approval was only obtained on October 29, 2025, prompting auditor emphasis of matter and indicating governance timing gaps / Incremental financial impact of ₹24 million recognized as past service cost due to New Labour Codes effective November 21, 2025, with implementation uncertainty as Central and State Rules remain pending, risking further cost pressures if wage definitions are expanded / Concentration risk in related party operations: Export sales (₹111 million noted specifically to Opella Healthcare International SAS) and material transactions with ultimate parent Opal JVco S.a.r.l following Sanofi's global restructuring in April 2025 create dependency on parent company stability / Operating cash flow deterioration of 60.2% YoY from ₹4,390 million in FY2024 to ₹1,748 million in FY2025, raising questions about working capital normalization and cash generation sustainability despite strong profit growth / Limited disclosure on geographic and customer concentration metrics (null values for customer/supplier concentration, segment-wise distribution), obscuring portfolio diversification and customer retention risks in consumer healthcare segment

Revenue from operations grew 21.6% year-over-year to Rs. 8,968 million in FY2025, demonstrating strong market demand and successful commercial execution across the consumer healthcare portfolio / Profit after tax increased 32.7% to Rs. 2,401 million with net profit margin of 26.8%, indicating superior operational leverage and pricing power as profit growth significantly outpaced revenue growth / Earnings per share improved from Rs. 78.59 in FY2024 to Rs. 104.27 in FY2025, a 32.7% increase that reflects efficient capital deployment and value creation for shareholders / Q4 FY2025 delivered the strongest quarterly performance with revenues of Rs. 2,556 million and PAT of Rs. 665 million, showing positive sequential momentum heading into FY2026 / Board recommended final dividend of Rs. 75 per share representing 71.9% payout ratio, demonstrating confidence in cash flow sustainability and commitment to shareholder returns despite unknown debt obligations / Exceptional items were minimal at negative Rs. 66 million, representing less than 3% of profit before tax, indicating earnings quality is primarily driven by recurring operational performance rather than one-time gains

Complete absence of cash flow data prevents assessment of operating cash generation, free cash flow adequacy, capex requirements, and ability to sustain the 71.9% dividend payout ratio without balance sheet stress / No balance sheet information disclosed beyond share capital of Rs. 230 million and reserves of Rs. 3,610 million, limiting visibility into debt levels, liquidity position, working capital efficiency, and overall financial leverage / Missing operational metrics including EBITDA, cost structure breakdown, inventory turnover, and receivables management prevent evaluation of operational efficiency and sustainability of the 26.8% net margin / Standalone entity structure with no subsidiaries, associates, or joint ventures may limit diversification opportunities, geographic expansion potential, and ability to hedge against category-specific headwinds in consumer healthcare / Tax expense of Rs. 802 million represents an effective tax rate of 25%, which is at the standard corporate rate, offering no tax efficiency advantage and leaving margins vulnerable to potential rate increases / No disclosure of forward-looking guidance, strategic initiatives, new product launches, capacity expansions, or pipeline projects limits visibility into growth sustainability beyond the current momentum in FY2025

Strong revenue growth of 21.6% YoY, with total revenue from operations reaching Rs. 8,968 million in FY2025 compared to Rs. 7,375 million in FY2024 / Profit after tax increased 32.7% to Rs. 2,401 million versus Rs. 1,810 million in the prior year, indicating significant operating leverage and margin expansion / Earnings per share improved substantially by 32.7% to Rs. 104.27 from Rs. 78.59, demonstrating strong shareholder value creation / Net profit margin of 26.8% reflects exceptional profitability in the consumer healthcare segment / Board recommended a generous final dividend of Rs. 75 per share (71.9% payout ratio), signaling management confidence in cash generation and financial strength / Q4 FY2025 revenue of Rs. 2,556 million marked the strongest quarterly performance, showing positive sequential and YoY momentum

Complete absence of cash flow data prevents assessment of operating cash generation, free cash flow sustainability, and capex coverage capability / Missing balance sheet details on debt levels, current assets, working capital, and liquidity ratios create uncertainty about financial flexibility and solvency / No disclosure of EBITDA, EBITDA margins, or operational efficiency metrics limits visibility into core business profitability and cost structure trends / Exceptional items of negative Rs. 66 million during FY2025 indicate one-time adjustments that could mask underlying operational performance / Tax rate of 25% and tax expense of Rs. 802 million represents a significant cost burden on profitability / Standalone entity structure with no subsidiaries, associates, or joint ventures may limit growth diversification and market expansion opportunities

Exceptional revenue growth of 21.25% YoY to ₹8,784 million driven by successful relaunch of all four recalled products throughout 2025 (Depura Adult in Q1, Combiflam Suspension in Q2, Allegra/Depura Kids in Q3) and export sales surge of 158% / Strong profitability with EBITDA margin of 36.28%, operating margin of 35.71%, and net profit margin of 26.62%, while PAT increased 31.9% to ₹2,387 million and EPS reached ₹104.27 / Debt-free balance sheet with ₹3,748 million in cash and cash equivalents, current ratio of 3.85, quick ratio of 3.37, and working capital of ₹3,659 million providing exceptional financial flexibility / Outstanding return metrics with ROE of 62.16% and ROA of 43.64%, demonstrating highly efficient capital deployment and strong earnings power relative to asset base / Accelerating Q4 momentum with domestic sales up 23% and export sales up 932% versus Q4 FY2024, indicating strong sequential improvement and successful execution of product relaunch strategy / Shareholder-friendly capital allocation with recommended final dividend of ₹75 per share (71.92% payout ratio) supported by robust free cash flow generation of ₹1,672 million despite ₹76 million capex

Significant operating cash flow decline to ₹1,748 million in FY2025 from ₹4,390 million in FY2024 (60.2% reduction) despite revenue growth, indicating potential working capital pressures or timing issues / Regulatory compliance concerns with ₹111 million in material related party transactions with Opella Healthcare International SAS occurring between October 10-28, 2025 before shareholder approval on October 29, 2025, resulting in auditor emphasis of matter / Ownership structure uncertainty following Sanofi's global sale of 50% controlling stake in Opella group to Clayton, Dubilier & Rice Fund XII on April 30, 2025, changing ultimate parent to Opal JVco S.a.r.l with potential integration risks / New Labour Code implementation effective November 21, 2025 already resulted in ₹24 million incremental past service cost for gratuity and compensated absences, with additional financial impacts pending finalization of Central and State Rules / FCF conversion ratio of 70.05% indicates only moderate conversion of profits to free cash flow, suggesting potential working capital inefficiencies despite strong reported earnings / Heavy concentration risk with material related party export transactions (limit increased from ₹1,100 million to ₹2,000 million) to single entity Opella Healthcare International SAS, creating revenue dependency concerns

Revenue from operations grew 21.25% YoY to 8,784 million, supported by successful relaunches of Depura Adult, Combiflam Suspension, Allegra Suspension, and Depura Kids. / Profitability is strong with EBITDA of 3,254 million (36.28% margin), EBIT margin implied by EBIT of 3,137 million, and net profit margin of 26.62%. / Balance sheet is very strong with zero debt (debt-to-equity 0, debt-to-assets 0) and cash/equivalents of 3,748 million. / Returns are high with ROE at 62.16% and ROA at 43.64%, indicating efficient capital deployment. / Liquidity is comfortable (current ratio 3.85, quick ratio 3.37) and free cash flow remained positive at 1,672 million with low capex of 76 million.

Operating cash flow fell sharply to 1,748 million in FY2025 from 4,390 million in FY2024, despite higher reported earnings, which weakens cash-conversion confidence. / Growth quality has a base-effect element: export sales rose 158% for FY2025 and 932% in Q4 partly versus a low base and prior recall disruptions. / Auditor highlighted an emphasis-of-matter on related-party export transactions (111 million executed before shareholder approval on October 29, 2025), indicating governance/compliance execution risk. / Regulatory uncertainty remains from New Labour Codes; the company already booked a 24 million incremental past-service cost and flagged potential further impact pending final rules. / High dividend payout (75 per share; 71.92% payout ratio) could constrain internal reinvestment flexibility if growth or compliance costs increase.